AD/PD 2021 | The impact of RGn530 in the treatment landscape of Alzheimer’s disease

Jacques Touchon, MD, PhD, University Hospital of Montpellier, Montpellier, France, details how the RGn530 photobiomodulation medical device could impact the treatment landscape of Alzheimer’s disease, which is a complex and multifactorial disease. Therefore, treatment strategies should target multiple disease aspects, such as amyloid β, tau, and inflammation. Prof. Touchon highlights RGn530’s action on inflammation and adds that this type of therapy could be used in combination with treatments targeting different aspects of the disease. This interview took place during the AD/PD™ 2021 conference.